Table 4

Changes in different variables between 3 and 24 months, using a mixed linear model

P value


Treatment A (n = 14)

Treatment B (n = 11)

Time

Treatment × Compliance × Time


DAS28

-1.8 (-2.6 to -1.0)

-1.9 (-2.8 to -1.0)

<0.001

0.59

ESRa

-0.62 (-1.07 to -0.18)

-0.49 (-0.99 to 0.02)

0.003

0.78

HAQ

-0.27 (-0.50 to -0.04)

-0.43 (-0.69 to -0.17)

<0.001

0.82

Leptina

0.25 (0.02 to 0.48)

0.32 (0.05 to 0.59)

<0.001

0.07

Adiponectin

1.66 (0.16 to 3.17)

2.33 (-0.27 to 4.93)

<0.001

0.058

Apolipoprotein A1

0.09 (-0.08 to 0.26)

0.19 (-0.01 to 0.39)

0.004

0.45

Apolipoprotein B

-0.06 (-0.16 to 0.03)

0.07 (-0.04 to 0.18)

0.59

0.33

ApoB/ApoA1

0.09 (-0.19 to 0.00)

-0.01 (-0.12 to 0.10)

0.023

0.56

P1NPa

-0.02 (-0.030 to 0.25)

-0.29 (-0.61 to 0.03)

0.004

0.82

CTX1a

-0.25 (-0.64 to 0.14)

-0.47 (-0.62 to 0.28)

<0.001

0.11

1CTPa

-0.05 (-0.27 to 0.16)

-0.21 (-0.46 to 0.04)

<0.001

0.76

P1NP/CTX-1a

0.23 (-0.04 to 0.49)

-0.10 (-0.41 to 0.21)

0.023

0.08

P1NP/1CTPa

0.03 (-0.28 to 0.34)

-0.08 (-0.44 to 0.28)

0.45

0.56

IGF-1a

0.06 (-0.07 to 0.18)

-0.02 (-0.17 to 0.13)

0.050

0.08

IGF-1 SD score

0.32 (-0.14 to 0.78)

0.02 (-0.52 to 0.56)

0.003

0.12


Data presented as mean (95% confidence interval). aArithmetic mean. Treatment A, methotrexate + sulphasalazine + hydroxychloroquine; treatment B, methotrexate +infliximab. DAS28, Disease Activity Score of 28 joints; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; apo, apolipoprotein; P1NP, procollagen type I N-terminal propeptide; CTX-1, C-terminal telopeptide of type I collagen; 1CTP, C-terminal propeptide of type I collagen; IGF-1, insulin-like growth factor-1; SD, standard deviation. Changes between 3 and 12 months and patients not compliant to respective treatment are not presented. P values given for the interactions with the main factor Time and the interactions with factor Time. Bold values are statistically significant.

Engvall et al. Arthritis Research & Therapy 2010 12:R197   doi:10.1186/ar3169

Open Data